Skip to main content
Equibles

Tetragon Partners GP Ltd

Position in KPTI — Karyopharm Therapeutics Inc.

CIK 1515070 GRAND CAYMAN, E9
Back to KPTI Full portfolio

Position in KPTI

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$0
-$295,120 QoQ
Shares Held
0
-100.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
2 quarters on record

Derivatives in KPTI

reported options exposure · as of Jun 30, 2026
CallValue
$2,445,431
CallShares
250,300
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Tetragon Partners GP Ltd holds $170,564,204 across 22 Biotechnology names.

# Ticker Company Shares Value (USD) Open
1 AUTL
Autolus Therapeutics plc
 9,500,000 $15,200,000
2 DFTX
Definium Therapeutics, Inc.
 286,990 $13,500,009
3 MBX
MBX Biosciences, Inc.
 203,543 $11,235,573
4 CLDX
Celldex Therapeutics, Inc.
 290,441 $10,807,309
5 RLAY
Relay Therapeutics, Inc.
 570,311 $10,670,518
6 ARWR
Arrowhead Pharmaceuticals, Inc.
 130,484 $10,635,750
7 PHVS
Pharvaris N.V.
 295,627 $10,222,781
8 IMVT
Immunovant, Inc.
 255,934 $9,861,137

All Filings in KPTI

Export CSV
3 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $2,445,431 250,300
2026-03-31 $295,120 52,984
2026-03-31 $278,500 50,000